Premium
Successful management of primary hypercholesterolaemia with simvastatin and low‐dose colestipol
Author(s) -
Simons Leon A,
Simons Judith,
Parfitt Annette
Publication year - 1992
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1992.tb137306.x
Subject(s) - simvastatin , medicine , apolipoprotein b , cholesterol , placebo , triglyceride , gastroenterology , adverse effect , cholestyramine , endocrinology , alternative medicine , pathology
Objective To examine whether a small dose of bile acid sequestrant used in combination with a hydroxymethylglutaryl coenzyme A reductase inhibitor is more effective in reducing serum and low‐density lipoprotein (LDL) cholesterol levels than inhibitor used alone. Design A randomised, double‐blind study. Setting Subjects receiving tertiary care at a hospital lipid clinic. Patients Subjects with severe primary hypercholesterolaemia (types IIa and IIb), already stabilised on a cholesterol‐lowering diet, with serum cholesterol levels of 7.0 mmol/L or more and triglyceride levels of 6.0 mmol/L or less. Sixty‐four subjects were randomly assigned to the treatment groups; three withdrew before any outcome observations; 61 completed the trial and their results were analysed. Interventions Subjects were randomly assigned to receive either colestipol placebo or colestipol 5 g or 10 g each morning in fixed dosage for 18 weeks. They simultaneously received incremental doses of simvastatin: placebo for six weeks, then 20 mg/night for six weeks, then 40 mg/night for a final six weeks. Main outcome measures Lipids, lipoproteins, and haematological and biochemical safety parameters were measured at the end of each treatment period. Adverse events were monitored. Results Respective maximum reductions (95% confidence intervals) in serum cholesterol, LDL cholesterol and apolipoprotein B (apo‐B) values in subjects taking combination therapy were 41% (38%–45%), 50% (46%–53%) and 43% (39%–46%), compared with lesser reductions of 32% (26%–37%), 38% (31%–45%) and 37% (32%–41%) in those taking simvastatin monotherapy. The percentage changes in LDL cholesterol with combination therapy were independent of baseline cholesterol level or lipid phenotype. Combination therapy reduced serum triglyceride levels by up to 24% (15%–32%) and increased high‐density lipoprotein (HDL) cholesterol levels by up to 9% (3%–15%). Three subjects withdrew within a few weeks because of severe gastrointestinal side effects related to colestipol; 19 experienced milder gastrointestinal side effects, 15 were taking combination therapy. Conclusions A combination of low‐dose colestipol and simvastatin was found to be more effective in reducing serum and LDL cholesterol than simvastatin used alone. Such combination therapy offers the possibility of improved cholesterol lowering without the need for full dosage of either drug.